Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Rubin MR, Cosman F, Lindsay R, Bilezikian JP
:max_bytes(150000):strip_icc()/HDC-GettyImages-2195485788-299e147644524b339a084114355dff83.jpg)
Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and LEADER (REWIND trial reference)
This finding complements results from an earlier study that revealed a role for Y1-R agonism in facilitating trans-differentiation of -cells into -cells 21
But it is also not remotely comparable to pharmaceutical GLP-1 medications in mechanism, evidence, or expected outcomes
US$ 24.89
US$ 22.39
US$ 26.32
US$ 25.92
US$ 25.77
US$ 24.53
US$ 20.60
US$ 24.77
US$ 25.27
US$ 25.81
US$ 23.66
US$ 28.93
